iPhot receives a 940K€ grant

Article

iPhot, the collaborative project for continuing the development of Imagine Eyes' rtx1 Adaptive Optics Retinal Camera has received a 940K€ (approximately $US1.35M) grant from France's National Research Agency (ANR) TecSan programme.

iPhot, the collaborative project for continuing the development of Imagine Eyes' rtx1 Adaptive Optics Retinal Camera has received a 940K€ (approximately $US1.35M) grant from France's National Research Agency (ANR) TecSan programme.

“The ultimate goal of the iPhot project is to optimize the process of adaptive-optics enabled retinal imaging in order to obtain morphological, quantitative and longitudinal information at the level of single photoreceptor cells in humans” notes Imagine Eyes' CEO Nicolas Chateau. Adding: “Clinical investigations related to this particular project will be focused on early detection of photoreceptor damage in cases of genetically or phenotypically defined inheritable retinal dystrophies. As the project and its technology advances, we plan to partner with additional clinical investigation sites to perform research on the healthy retina as well as other retinal diseases.”

“Unfortunately, most cases retinal of disease are diagnosed only once the patient has suffered significant, irreparable vision loss” says Pr. Michel Paques, iPhot's Project Coordinator, from the Quinze-Vingts hospital. “Functional testing detects visual impairment only once a significant proportion of cells have degenerated. More importantly, functional defects, and the associated morphological changes at the level of outer segments, can precede cell loss. The current imaging technologies that are used to diagnose and monitor the effectiveness of treatment lack the cellular level resolution needed to observe the retinal microstructures causing the visual dysfunction. The comprehensive analysis of the relationship between structural and functional parameters will guide both prognostic assessment and therapeutic decision making in affected patients. It should equally provide clues to discriminate and quantify irreversible versus reversible lesions.”

To view images obtained with Imagine Eyes' adaptive-optics retinal camera, click here.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.